Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. (AQST) reported that its President and CEO, Daniel Barber, sold common stock pursuant to a Rule 10b5-1 trading plan. On 2026-08-17, he sold 25,000 shares of common stock in open market or private transactions at a weighted average price of $4.2867 per share, with individual sale prices ranging from $4.24 to $4.35 per share. Following this transaction, Barber directly holds 585,574 shares of Aquestive Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares

Net Sell 1 txn

Insider Barber Daniel

Role President and CEO

Sold 25,000 shs ($107K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	25,000	$4.2867	$107K

Holdings After Transaction: Common Stock — 585,574 shares (Direct)

Footnotes (1)

1. F1. The reported transaction involves sale transactions from $4.24 to $4.35 per share. The weighted average price per share was $4.2867. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 25,000 shares Weighted average sale price: $4.2867 per share Sale price range: $4.24 to $4.35 per share +1 more

4 metrics

Shares sold 25,000 shares Common stock sold by Daniel Barber on 2026-08-17

Weighted average sale price $4.2867 per share Weighted average for 25,000 shares sold on 2026-08-17

Sale price range $4.24 to $4.35 per share Range of individual sale prices for the reported transaction

Shares held after transaction 585,574 shares Direct holdings of Daniel Barber after the 25,000-share sale

Key Terms

weighted average price per share, sale in open market or private transaction, Rule 10b5-1 trading plan

3 terms

weighted average price per share financial

"The weighted average price per share was $4.2867."

sale in open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

Rule 10b5-1 trading plan regulatory

"form-level Rule 10b5-1 checkbox indicates trades under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

What insider transaction did AQST report for Daniel Barber on this Form 4?

Daniel Barber, President and CEO of AQST, reported selling 25,000 shares of common stock. The sale occurred on 2026-08-17 in open market or private transactions at a weighted average price of $4.2867 per share.

At what prices were Daniel Barber’s AQST shares sold?

Daniel Barber’s 25,000 AQST shares were sold at prices ranging from $4.24 to $4.35 per share. The filing reports a $4.2867 weighted average price across these individual sale transactions.

How many AQST shares does Daniel Barber hold after the reported sale?

After the reported transaction, Daniel Barber directly holds 585,574 shares of Aquestive Therapeutics common stock. This post-transaction holding reflects his remaining direct ownership following the 25,000-share sale on 2026-08-17.

Was Daniel Barber’s AQST stock sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 indicates the transaction was effected under a Rule 10b5-1 trading plan. Such plans pre-arrange trades according to set instructions, which can reduce the informational value of the transaction’s timing.

What type of transaction code was used for Daniel Barber’s AQST stock sale?

The sale is reported under transaction code S, described as a sale in open market or private transaction. This code confirms the transaction involved a disposition of common stock rather than an option exercise or grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 04:13 PM Accepted by SEC EDGAR 08/18/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barber Daniel

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S		25,000	D	$4.2867(1)	585,574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involves sale transactions from $4.24 to $4.35 per share. The weighted average price per share was $4.2867. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)